1. Drucker DJ，Nauck MA. The incretin system：glucagon-like peptide-1 receptor agonists and dipeptidy1 peptidase-4 inhibitors in type 2 diabetes. Lancet，2006，368：1696-1705.

2. Ahrens B. Dipeptidy1 peptidase-4 inhibitors，clinical data and clinical implications. Diabetes Care，2007，30：1344-1350.

3. Gilbert MP，Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med，2009，122：S11-S24.

4. 潘长玉. 从近期研究看GLP-1对心血管的作用.中华内分泌代谢杂志，2010，26（增录）：5a-1-4.

5. Klonoff DC，Buse JB，Nielsen LL，et al. Exenatide effects on diabetes，obesity，cardiovascular risk factors，and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years，Current Med Res Opin，2008，24：275-286.

6. Garber A，Henry R，Ratner R，et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes （LEAD-3 Mono）：a randomized，52-week，phase 3，double blind，parallel-treatment trial. Lancet，2009，373：473-481.

7. 潘长玉，姬秋和，杨文英，等.2型糖尿病患者维格列汀与阿卡波糖单药治疗的比较研究——24周多中心，随机、双盲、双模拟、阳性对照试验. 中华内分泌代谢杂志，2009，25：386-390.

8. Pratley RE. Overview of glucagon-like peptide-1 analogs and dipetidy1peptidase-4 inhibitors for type 2 diabetes. Medscape J Med，2008，10：171.

9. Nauck MA. Unraveling the science of incretin biology. Am J Med，2009，122（6）：S3-S10.

10. Neumiller JJ，Wood L，Campbell RK et al. Dipeptidy1 peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy，2010，30（5）：463-484.

11. Hansen L，Hartmann B，Bisgaard T，et al. Somatostain restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab，2000，278（6）：E1010-E1018.

12. Holst JJ，Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-Ⅳinhibitors. Diabetologia.2005，48（4）：612-615.

13. Waget A，Cabou C，Masseboeuf M，et al.Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology，201，152（8）：3018-3029.

14. Bock G，Dalla Man C，Micheletto F，et al. The effect of DPP-4 inhibition with sitagliptin and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.Clin Endocrinol，2010，73（2）：189-196.

15. Lamont BJ，Li Y，Kwan E，et al. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.J Clin Invest，2012，122（1）：388-402.

16. Hjllund KR，Deacon CF，Holst JJ.Dipeptidy1 peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1（GLP-1） to a greater extent than peripheral concentrations in anaesthetized pigs. Diabetologia，2011，54（8）：2206-2208.

17. Kohan AB，Yoder SM，Tso P，et al. Using the lymphatics to study nutrient absorption and the secretion of gastrointestinal hormones.Physiol Behav，2011，105（1）：82-88.

18. Strain WB，Lukashevich v，Kothny W，et al. Individualised treatment targets for elderly patients withtype 2 diabetes using vildagliptin add-on or lone therapy（INTERVAL）：a 24 week，randomised，double-blind，placebo-controlled study.Lancet 2013，382：409-416.

19. Aroda VR，Henry RR，Han J，et al.Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors：meta-analysis and systematic review.Clin Ther. 2012，34（6）：1247-1258.

20. Schweizer A1，Dejager S，Foley JE，et al. Assessing the general safety and tolerability of vildagliptin：value of pooled analyses from a large safety database versus evaluation of individual studies.Vasc Health Risk Manag. 2011，7：49-57.

21. Fujiwara K，Gotoh K，Chiba S，et al. Intraportal administration of DPP-Ⅳ inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats.J Neurochem，2012，121（1）：66-76.

22. Foley JE，Liqueros-Saulan M，He YL，et al. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 2 diabetes. J Clin Endocrinol Metab，2012，97（10）：3799-3806.

23. Treiman M，Elvewkjaer M，Engstom T，et al. Glucagon-like peptide 1-a cardiologic dimension. Trends Cardiovasc Med，2010，20（1）：8-12.